Amylyx Pharmaceuticals (AMLX)
(Delayed Data from NSDQ)
$13.31 USD
+0.06 (0.45%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $13.32 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AMLX 13.31 +0.06(0.45%)
Will AMLX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AMLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMLX
Wall Street Analysts See a 105.22% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High?
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy
AMLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock?
Other News for AMLX
AMLX makes New 52 Week Closing High on September 19
New 52 Week Closing High appears for AMLX after 3.76% move
New 52 Week Closing High appears for AMLX after 6.77% move
New 52 Week Closing High appears for AMLX after 0.93% move
Goldman Sachs Raises Price Target for AMLX to $20, Maintains Buy Rating | AMLX Stock News